Intercept Pharmaceuticals Inc (ICPT)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Jerome B. Durso |
| Employees: | 440 |
| Web site: | interceptpharma.com |
|
305 MADISON AVENUE, MORRISTOWN, NJ, 07960
646-747-1000
| |
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Are you looking for this stock instead?
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. Intercept also has a license agreement with Aralez Pharmaceuticals Canada to develop and commercialize bezafibrate.
Please log in first to see chart